nach oben

Drugs

Erschienen in:

01.10.2020 | AdisInsight Report

Bulevirtide: First Approval

verfasst von: Connie Kang, Yahiya Y. Syed

Erschienen in: Drugs | Ausgabe 15/2020

Einloggen, um Zugang zu erhalten

Abstract

Bulevirtide (Hepcludex^®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.

MYR Pharmaceuticals. MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX^® [media release]. 4 Aug 2020. https://www.prnewswire.com.

European Medicines Agency. Hepcludex (bulevirtide) powder for solution for injection: EU summary of product characteristics. 2020. https://ec.europa.eu. Accessed 31 Aug 2020.

Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor Myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8.CrossRef

Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B. J Hepatol. 2016;65(3):483–9.CrossRef

European Medicines Agency. Hepcludex: EPAR—medicine overview. 2020. https://www.ema.europa.eu. Accessed 31 Aug 2020.

MYR Pharmaceuticals. MYR Pharmaceuticals—treatment of HBV & HDV infections. 2020. https://myr-pharma.com. Accessed 31 Aug 2020.

Maxwell Biotech Venture Fund. Maxwell Biotech Venture Fund invests in hepatitis B/D clinical program [media release]. 15 Mar 2012. https://www.rvc.ru.

Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–7.CrossRef

European Medicines Agency. Hepcludex: EU assessment report. 2020. https://www.ema.europa.eu. Accessed 31 Aug 2020.

10.

Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection [abstract no. GS-005]. J Hepatol. 2018;68(Suppl 1):S3.

11.

Wedemeyer H, Schoneweis K, Bogomolov PO, et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in with PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection [abstract no. GS-13]. J Hepatol. 2019;70(1):e81.

12.

Wedemeyer H, Schoneweis K, Bogomolov P, et al. Safety and efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-interferon alpha 2a or tenofovir in patients with chronic HBV/ HDV co-infection: week 24 interim results of the MYR203 extension study [abstract no. 85]. Hepatology. 2019;70(Suppl 1):58A-9A.

13.

Haag M, Hofmann U, Mürdter TE, et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring epatitis B therapy by a novel Na⁺-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem. 2015;407:6815–25.CrossRef

14.

Hepatera. Maxwell Biotech portfolio company Hepatera announces proof-of-concept clinical results with Myrcludex B, a novel entry inhibitor for treatment of chronic hepatitis B and Delta [media release]. 21 Oct 2014. https://www.hepatera.ru.

Titel: Bulevirtide: First Approval
verfasst von: Connie Kang
Yahiya Y. Syed
Publikationsdatum: 01.10.2020
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2020
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-020-01400-1

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2020

Triheptanoin: First Approval

Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer

Belantamab Mafodotin: First Approval

Atezolizumab: A Review in Extensive-Stage SCLC

Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs